Sana Biotechnology said a type 1 diabetes (T1D) patient received an allogeneic primary islet cell transplantation without ...

Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 ...

Sana Biotechnology has shared early data for its investigational allogeneic cell therapy being studied in one patient with ...

The following is a summary of “Identification of a pancreatic stellate cell gene signature and lncRNA interactions associated ...

Sonja Schrepfer and the team at Sana. The clinical data are highly promising for patients and provide the first evidence in humans for overcoming allogeneic and autoimmune rejection with pancreatic ...

We view the insights from the current study as directly applicable to developing SC451, our HIP-modified, stem cell-derived pancreatic islet cell program for the treatment of type 1 diabetes.

Sana Biotechnology's first-in-human study shows UP421 pancreatic islet cells surviving and functioning in type 1 diabetes ...

an allogeneic primary islet cell therapy engineered with Sana’s hypoimmune (HIP) technology, into a patient with type 1 diabetes without the use of any immunosuppression. The study was conducted ...

Sana Biotechnology (SANA) announced initial results from an investigator-sponsored, first-in-human study transplanting UP421, an allogeneic ...

Sana Biotechnology, Inc. shares surge as a breakthrough in diabetes therapy sparks investor interest. Click for my updated ...

After years of controversy, stem cells are on the cusp of cures for conditions like epilepsy and type 1 diabetes.